Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (3): 253-257.
DOI: 10.19803/j.1672-8629.20220367

Previous Articles     Next Articles

Mechanisms of Qingkailing soft capsules against coronavirus pneumonia based on network pharmacology and experimental verification

CHEN Mengping1,2, WANG Yaxin2, YAO Rongmei2, BAO Lei2, ZHAO Ronghua2, SUN Jing2, GENG Zihan2, BAO Yanyan2, DAI Min1, GUO Shanshan2,*, CUI Xiaolan2#   

  1. 1School of Pharmacy, Anhui University of Traditional Chinese Medicine, Hefei Anhui 230012, China;
    2Biosecurity Laboratory, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
  • Received:2022-06-30 Online:2023-03-15 Published:2023-03-17

Abstract: Objective To study the targets and signal pathways of Qingkailing soft capsules in the treatment of coronavirus pneumonia based on network pharmacology. Methods The main chemical ingredients of Qingkailing soft capsules were obtained by searching the TCMSP database for related literature that was published between inception and June 28, 2022. The potential targets of Qingkailing soft capsules in the treatment of coronavirus pneumonia were obtained from Swiss Target Prediction and GeneCards database. A PPI interaction network and “drug-component-target” network were constructed before the potential targets were analyzed via KEGG pathway enrichment. The effect of Qingkailing soft capsules on lung indexes was detected, and the contents of IL-6, SOD in lung tissues and those of PGE2 and CAMP in the hypothalamus were detected by Elisa. Results The “drug-component-target” network consisted of 296 edges, 7 drug nodes, 33 compound nodes and 112 target nodes. Compared with the model group, the lung indexes of the Qingkailing soft capsule group decreased significantly(P<0.01), so did the contents of IL-6 in lung tissues and PGE2 in the hypothalamus(P<0.01). Conclusion Qingkailing soft capsules may play a role in the treatment of coronavirus pneumonia by regulating inflammatory mediators and febrile mediators.

Key words: Qingkailing, soft capsules, network pharmacology, HCoV-229E, lung-attacking damp-heat epidemic toxin

CLC Number: